Immuron Limited · ASX:IMC
Immuron — Investor Presentation (February 2024)
11 slides from Immuron's investor presentation, Feb 9, 2024
Slide 1: Immuron Presentation - Monsoon Communications
IMMUreNn PRESENTATION MONSOON COMMUNICATIONS 8 FEBRUARY, 2024 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressio
Slide 3: Revenue Generating with Strong Pipeline
REVENUE GENERATING WITH STRONG PIPELINE © Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Financial Snapshot 227,798,346 227,798,346 Total Options 12,
Slide 4: Revenue Generating with Strong Pipeline
REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Pipeline Snapshot 30-Jun-23 31-Dec-23 Travelan (IMM-124E) - Ph
Slide 5: Distribution Capability
DISTRIBUTION CAPABILITY Australia USA Canada Retail Pharmacy a ao B28 Vv va ww ao Established E-commerce a aS ey @A Developing Key Commentary Australia * Retail network includes over 3,500 pharmacies * Online sales of both Travelan® and Protectyn® * Protectyn® is distributed by Osborne Health Suppli
Slide 6: Net Sales
Jz + iS « * es Net Sales FY23: A$1.16 million 1HFY24: A$1.85 million 132% higher than pre- pandemic period 1HFY20 ImmMUren lt Net Sales FY23: A$0.64 million 1HFY24: A$0.48 million 6% lower than pre- pandemic period 1HFY20 STRONG SALES GROWTH IN Australia Short term resident returns in Oct 23 were 47
Slide 7: Technology Platform for Gut Mediated Diseases
TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES © Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to
Slide 8: Strong Pipeline with Near Term Milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES © Immuron’s Clinical Programs ) Compound or Indication Phase Phase Phase = Market brand name ! i ul Traveler’s IMM-124E " ‘Travelaii® Diarrhea ETEC |MMUILON challenge Clostridioides IMM-529 difficile =~ IMmMU Infection & Recurrence Our Partners’ Clinical Pro
Slide 9: Near Term Milestones Anticipated to Drive Value
NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE © FDA IND? approved for single daily dose IMM- IRB Approval* Initiated IMM-124E ETEC? 100% of patients enrolled + Completion of In-patient Topline results for IMM- * 124€ ETEC? clinical trial Clinical Study Report Travelan® 124€ ETEC? CHIMS clinical CH
Slide 10: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: of volunteers 10.3109/00365521.2011.574726 Clinical Evaluation of Travelan® an Oral Prop
Slide 11: Contact Information
ImmMUren STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: BX EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172